Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Lung Transplantation Overview 6
Therapeutics Development 7
Pipeline Products for Lung Transplantation - Overview 7
Lung Transplantation - Therapeutics under Development by Companies 8
Lung Transplantation - Pipeline Products Glance 9
Clinical Stage Products 9
Early Stage Products 10
Lung Transplantation - Products under Development by Companies 11
Lung Transplantation - Companies Involved in Therapeutics Development 12
Apeptico Forschung und Entwicklung GmbH 12
Kamada Ltd. 13
Proteo, Inc. 14
Quark Pharmaceuticals, Inc. 15
Lung Transplantation - Therapeutics Assessment 16
Assessment by Monotherapy Products 16
Assessment by Target 17
Assessment by Mechanism of Action 19
Assessment by Route of Administration 21
Assessment by Molecule Type 23
Drug Profiles 25
alpha-1 proteinase inhibitor (human) - Drug Profile 25
Product Description 25
Mechanism of Action 25
R&D Progress 25
FX-06 - Drug Profile 27
Product Description 27
Mechanism of Action 27
R&D Progress 27
PB-01 - Drug Profile 29
Product Description 29
Mechanism of Action 29
R&D Progress 29
QPLI-1 - Drug Profile 31
Product Description 31
Mechanism of Action 31
R&D Progress 31
R-503 - Drug Profile 32
Product Description 32
Mechanism of Action 32
R&D Progress 32
R-801 - Drug Profile 34
Product Description 34
Mechanism of Action 34
R&D Progress 34
solnatide - Drug Profile 36
Product Description 36
Mechanism of Action 36
R&D Progress 36
tiprelestat - Drug Profile 39
Product Description 39
Mechanism of Action 39
R&D Progress 39
Lung Transplantation - Recent Pipeline Updates 42
Lung Transplantation - Dormant Projects 49
Lung Transplantation - Product Development Milestones 50
Featured News & Press Releases 50
Apr 06, 2016: Kamada Announces Initiation of Phase 2 Clinical Trial with Intravenous Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 50
Jun 22, 2015: Kamada Collaborates with Baxalta on Phase 1/2 Clinical Trial with Alpha-1 Antitrypsin for the Prevention of Lung Transplant Rejection 51
Mar 12, 2015: Elafin combined with cyclosporine promises to overcome limitations of cyclosporine for preventing irreversible damage to transplanted organs 52
Apr 17, 2013: APEPTICO initiates phase II clinical trial with AP301 in patients with primary graft dysfunction following lung transplantation 53
Dec 06, 2011: Proteo And Its Subsidiary Announce Major Advances In Elafin Development Program 53
Sep 08, 2009: APEPTICO Presents Lead Product AP301 At Annual Congress Of European Respiratory Society In Vienna, Austria 54
Appendix 56
Methodology 56
Coverage 56
Secondary Research 56
Primary Research 56
Expert Panel Validation 56
Contact Us 56
Disclaimer 57
List of Tables
Number of Products under Development for Lung Transplantation, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Comparative Analysis by Early Stage Development, H1 2016 10
Products under Development by Companies, H1 2016 11
Lung Transplantation - Pipeline by Apeptico Forschung und Entwicklung GmbH, H1 2016 12
Lung Transplantation - Pipeline by Kamada Ltd., H1 2016 13
Lung Transplantation - Pipeline by Proteo, Inc., H1 2016 14
Lung Transplantation - Pipeline by Quark Pharmaceuticals, Inc., H1 2016 15
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Stage and Target, H1 2016 18
Number of Products by Stage and Mechanism of Action, H1 2016 20
Number of Products by Stage and Route of Administration, H1 2016 22
Number of Products by Stage and Molecule Type, H1 2016 24
Lung Transplantation Therapeutics - Recent Pipeline Updates, H1 2016 42
Lung Transplantation - Dormant Projects, H1 2016 49
List of Figures
Number of Products under Development for Lung Transplantation, H1 2016 7
Number of Products under Development by Companies, H1 2016 8
Comparative Analysis by Clinical Stage Development, H1 2016 9
Assessment by Monotherapy Products, H1 2016 16
Number of Products by Targets, H1 2016 17
Number of Products by Stage and Targets, H1 2016 17
Number of Products by Mechanism of Actions, H1 2016 19
Number of Products by Stage and Mechanism of Actions, H1 2016 19
Number of Products by Routes of Administration, H1 2016 21
Number of Products by Stage and Routes of Administration, H1 2016 21
Number of Products by Molecule Types, H1 2016 23
Number of Products by Stage and Molecule Types, H1 2016 23